Bo pharma bv and bo esthetics bv are medical device distribution companies founded in 2004 and 2010 respectively. They have a successful track record in the Benelux region, focusing on dermatology. The companies hold exclusive licenses for various medical devices from companies in the US and Europe. Their products are used for conditions like varicose veins, skin cancer detection and treatment, wrinkle reduction, and acne. The companies aim to expand into Scandinavian markets due to opportunities in dermatology and aesthetics.

1. Company presentation
bo pharma bv (est. 2004)
bo esthetics bv (est. 2010)
Henk-Peter Oonk MD MBA
CEO

2. Contents
• Executive summary
• History
• Current business

3. Executive Summary
• Successful distributor in (cos-) medical devices in Benelux:
– Focus in core specialty: dermatology
– Sound financial track record
– Strong name in US, the cradle for medical devices start-ups & companies: our licensors
• Strong market opportunity in Scandinavia:
– Skin cancer incidence is rising rapidly in North-western Europe, with it’s light-skinned
population
– Cosmetic market is growing despite economic malaise
– Business opportunities in these countries with similarities in healthcare
structure/organisation and GDP/per capita
• Solid financials:
– The company is by far the largest independent distributor in North-western Europe

4. History
• The company was founded in March 2004 by the two founders
and current directors, Cees de Bondt and Henk-Peter Oonk,
both with a pharma/biotech background
• Initially, the company focussed on over-the counter drugs (OTC)
through automatic vending systems:
– Successful @ start
– Placement @ airports/larger corporations
– Stopped in 2006 due to more stringent drug law
– Name ‘pharma’ kept
– Diversification into medical devices (2006) and cosmedic devices &
injectables (2010)

5. Board & Management Team
Board of Directors:
• Henk-Peter Oonk, CEO/CMO
• Cees de Bondt, CFO/COO

6. • Henk-Peter Oonk was born in Utrecht in 1964. He followed his secondary school at the Revius Lyceum in Doorn (The
Netherlands) and received the Atheneum diploma in 1984. He received a first master in Medical Biology at the Utrecht
University in 1990 and then joined the pharmaceutical industry, which he had came to know as VP of the student
association looking for sponsoring
• After a career in sales at Rhone-Poulenc Rorer (now the French part of Aventis) and at Yamanouchi, he continued his
career in marketing at Hoechst Marion Roussel (the German part of Aventis). In the years to follow he launched two
successful brands and received his master in Business Administration from Brunel University
• In 1998 he took his career on an international level and become European marketing manager at the Paris-based
European HQ of Biogen, a US-based biotech firm. At the end of 1999 he was asked to lead the Benelux organisation,
which he combined with his board membership of the Dutch pharmaceutical Association, NEFARMA
• In the 5 years to follow, he build the most successful subsidiary, also with the help of Cees de Bondt, who he met in 1999
looking for way to enhance sales team effectiveness
• In 2004 they decided to start their own business, bo pharma was born. That year he also started with his last study,
Medicine at the Groningen University
• In 2008 Henk-Peter received his medical degree and became MD. At bo pharma, Henk-Peter acts as the CEO/CMO.
• Henk-Peter is married to Aleida Dijkstra, dermatologist, with who he shares 5 children. The family lives in Blaricum

7. • Cees de Bondt was born in Zwolle in 1959. He followed his secondary school and a economic education at the Meander
College in Amersfoort (The Netherlands) and received his diploma in 1979
• After a in between year in mathematics and statistics he started his business career in the pharmaceutical industry at
Zambon and continued it after three years at Bayer as a sales rep
• In the following years he worked as a Sales Manager at Pharbita (part of the Medic Group) to finish his pharmaceutical
career at Organon in the position of National Sales Manager responsible for the fertility product group. In 1997 he
became partner in Targa Training, in that period one of the largest training and consultancy firms dedicated to the
Healthcare industry in the Netherlands. He specialised in product introduction concepts and personal coaching
• In 1999 he met Henk-Peter Oonk, at that time General Manager of the Biogen Benelux organisation, who became a loyal
customer for several years
• In 2004 he sold his share in Targa Training and decided with Henk-Peter to start their own business, bo pharma was born.
At bo pharma, Cees acts as the CFO/COO
• Cees is living together with Arlette Goddijn in Noorwijk and has two grown up sons

8. HQ
• Offices: the company is located in a former bio-diary farm, close to
Amsterdam (15 min). Cannenburgerweg 11-B, 1244 RE in Ankeveen, The
Netherlands.
• Warehouse: is located at the Constructieweg 7, 1271 EN in Huizen, The
Netherlands.

9. HQ

10. Current business
 Currently, the company focusses on the Benelux area
 Key target audience:
• 1: Dermatologists (350): VNUS product (for the treatment of varicose veins), Ambulight
product (to treat skin cancer outside the hospital) and the esthetic portfolio (an activity
of bo esthetics bv)
• 2: Plastic surgeons (150): esthetic portfolio
 Results:
• Market leader in Varicosis, nr 1 country in sales after USA!
• Only distributor with COVIDIEN group
• Strong in dermato-oncology with products to detect and treat skincancer
• Successful start bo esthetics bv, contracts with Bergman Clinics signed
• Online retail franchise started in 2012

11. Current business (2)
 2 legal entities, one target group
• bo pharma bv focuses on medical devices. Key targets include dermatologists in hospitals
and specialty clinics (Zelfstandige Behandelcentra (ZBC’s)). Key products changing the
treatment modality and offering better care at lower cost:
 VNUS catheter for varicose veins. No longer expensive OR needed, a treatment room at
the outdoor clinic will do
 Ambulight for skin cancer. No longer do patients have to stay 3 hours in the hospital as
they can can be treated
 Verisante for 2-second skin cancer detection a very promising future
• bo esthetics bv focusses on esthetical devices and products. Key targets include
dermatologists in (cosmetic) clinics.
 Dermal fillers like Stylage and PRP offer wrinkle reduction and skin rejuvenation
 Lasers offer rejuvenation and treatment of pigmented and vascular lesions
 Myoscince IOVERA device a breakthrough for dynamic wrinkles for those who DO NOT
want Botox

12. Current business (3)
 Reasons for success:
• Sales
­ Strong network in dermatology
­ Interesting and large product portfolio in dermatology
­ 60% of time spend in OR’s/treatment rooms
­ Focus on contribution margin
• Marketing
­ Strong in TV/internet & social media (Facebook, Twitter & LinkedIn)
­ In-house demo’s/seminars: over 600 physicians in our house the last 3 years
• Medical
­ Contacts with key in Ministry of Health & reimbursement
­ Clinical / R&D capability: ability to help small start-ups with interesting products to get
access to market
­ CME accredited courses in-house

13. Products in exclusive license
bo pharma bv
Year Product Indication Company
2006 - 2011 Resaflex RFA catheter Pain in FBSS MRT Srl, Boara Pisani
Italy
2007 - VNUS RFA catheter Varicosis Covidien Inc,
New-York USA
2009 - Trellis Thrombosis Covidien Inc,
New-York, USA
2011 Ambulight Skin Cancer Ambicare Health Ltd,
UK
2012 Aura Skin Cancer Verisante, Canada

14. Products in exclusive license
bo esthetics bv
Year Product Indication Company
2010 Stylage Dermal Filler Laboratoires Vivacy
SA, Paris France
2010 Regenlab PRP Rejuvenation Regenlab SA, Geneva
Switzerland
2010 Elos Rejuvenation Syneron, Tel-Aviv
Israel
2011 Iovera Wrinkles Myoscience Inc,
Redwood City USA
2012 Lustre Acne Ambicare Health Ltd,
UK